

Allergen Immunotherapy Products

FINAL COMPREHENSIVE RESEARCH PLAN

June 2015

Study Team: Environmental Scan

ODPRN Drug Class Review Proposal: Environmental Scan

Objectives

1. To summarize the pharmacy benefit programs for allergen immunotherapy in Ontario, across Canada and in select international jurisdictions
2. To determine the impact of different reimbursement schemes for allergen immunotherapy on patient access, quality of life and/or utilization and costs
3. To summarize the guidelines for allergen immunotherapy, as well as guidelines for management of patients with allergic rhinitis

Study Questions

1. How is allergen immunotherapy currently being accessed in publicly funded programs across Canada as well as internationally?
2. What is the impact of different reimbursement schemes for allergen immunotherapy on patient access, quality of life and/or utilization and costs?
3. Does sex, gender or socioeconomic status play an important role in any of the analyses described?

Objective 1: Pharmacy Benefit Programs in Ontario, across Canada and internationally

Study Design:	<u>Design:</u> summary of available information available through the Internet; interviews with individuals at the government agencies responsible for the public drug plan <u>Data sources:</u> Internet, direct contact with individuals
Study Population:	<ul style="list-style-type: none"> • Canada: provincial/territorial public plans • England, Wales, Northern Ireland, Scotland: NICE (National Institute for Health and Care Excellence) • Australia: Pharmaceutical Benefits Scheme • United States: Medicare, Veterans Affairs • New Zealand: PHARMAC (Pharmaceutical Management Agency)
Intervention:	Allergen immunotherapy: <ul style="list-style-type: none"> • venom subcutaneous immunotherapy (SCIT) • environmental (pollen and non-pollen) subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT)
Outcome(s) of Interest:	Drug Reimbursement Criteria and Policies: <ul style="list-style-type: none"> • Restricted Access vs. General Benefit • Specific restriction criteria

Objective 2: Impact of different drug reimbursement schemes for drugs for treatment of ADHD

Study Design:	<u>Design:</u> Literature review <u>Data sources:</u> Medline, EMBASE, Cochrane Collection, Grey literature
Study Population:	Allergen immunotherapy
Intervention:	Various drug reimbursement schemes, including general benefits, step therapy, special authorization
Outcome(s) of Interest:	Indirect/direct measurements of clinical outcomes, patient satisfaction, quality of life, utilization and/or costs, functionality at work, days of productivity at work

Objective 3: Guidelines for use of allergen immunotherapy

Study Design:	<u>Design:</u> Literature review <u>Data sources:</u> Medline, EMBASE, Cochrane Collection, Grey literature
Study Population:	Allergen immunotherapy
Intervention:	Guidelines/recommendations for the use of allergen immunotherapy
Outcome(s) of Interest:	Published guidelines by various organizations <ul style="list-style-type: none"> • Cox et al. Allergen immunotherapy: a practice parameter, 3rd update. JACI 2011;127:S1-55. • Calderon et al. Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement. Pediatr Allergy Immunol 2012;23:300-306. • Walker et al. Immunotherapy for allergic rhinitis. Clin Exp Allergy 2011;41:1177-1200 • Bousquet et al. Sublingual immunotherapy. World Allergy Organization. WAO J 2009;64 (suppl 91): 1-59 • Sussman G. Guidelines for the use of allergen immunotherapy (Canadian Society of Allergy and Clinical Immunology). CMAJ 1995;152:1413-9.